Colinz Laboratories

Colinz Laboratories EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Colinz Laboratories (531210.BO) as of Oct 16, 2026 is 1.97 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 3.08 % — a change of -36.15% (lower).

EBIT/Assets

1.97 %

YoY

-36.15%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Colinz Laboratories is 2026 1.97 % . Operating Income to Assets Ratio (EBIT/Assets) of Colinz Laboratories was 2025 3.08 % . It decreases by -36.15% lower compared to the previous year.

The Colinz Laboratories EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
1.47 INR
Jan 1, 2020
1.23 INR
Jan 1, 2021
1.39 INR
Jan 1, 2022
3.88 INR
Jan 1, 2023
4.92 INR
Jan 1, 2024
3.70 INR
Jan 1, 2025
3.08 INR
Jan 1, 2026
1.97 INR
The Colinz Laboratories EBIT/Assets history
YEAREBIT/AssetsYoY
1.97 %-36.15%
3.08 %-16.85%
3.70 %-24.78%
4.92 %+27.00%
3.88 %+178.50%
1.39 %+13.63%
1.23 %-16.61%
1.47 %+2.42%
1.43 %-3.83%
1.49 %-13.89%
1.73 %+17.80%
1.47 %+4.99%
1.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Colinz Laboratories Stock analysis

What does Colinz Laboratories do? Colinz Laboratories Ltd, listed on the Bombay Stock Exchange with ticker 531210.BO and ISIN INE923C01011, is a pharmaceutical company headquartered in Mumbai, India. The company operates within the Health Care sector, specifically in the Pharmaceuticals industry. It went public through an IPO on January 13, 2004. Colinz Laboratories is engaged in the manufacturing and marketing of pharmaceutical formulations across various dosage forms, including tablets, capsules, granules, liquid orals, injectables, ointments, and creams. The company's product portfolio targets several medical conditions, such as hypertension, cholesterol, diabetes, piles, pyrexia, and malaria, with specific offerings for gynecological treatments like morning sickness, infertility, intrauterine growth restriction (IUGR), and pregnancy maintenance. Additionally, it provides hematinic, antispasmodic, anti-inflammatory, anti-allergic, and medicated shampoo products. Colinz Laboratories markets its products directly within several Indian states, including Maharashtra, Karnataka, Andhra Pradesh, Gujarat, Rajasthan, Madhya Pradesh, Chhattisgarh, and West Bengal, utilizing its own marketing team. The company's website is www.colinz.com. It is important to note that the company's operations and product details are based on the provided information without additional verification. Colinz Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Colinz Laboratories stock

Operating Income to Assets Ratio (EBIT/Assets) of Colinz Laboratories is 1.97 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of Colinz Laboratories changed from 3.08 % to 1.97 %, representing a -36.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Colinz Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Colinz Laboratories with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Colinz Laboratories

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Colinz Laboratories